Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET

Company Participants

Sherry Aulin - CFO

Ian Mortimer - President and CEO

Dr. Chris Kenney - CMO

Dr. Chris Von Seggern - Chief Commercial Officer

Conference Call Participants

Tessa Romero - J.P. Morgan

Paul Matteis - Stifel

Brian Abrahams - RBC Capital Markets

Andrew Tsai - Jefferies

Paul Choi - Goldman Sachs

Joseph Thome - TD Cowen

Danielle Brill - Raymond James

Laura Chico - Wedbush Securities

Mohit Bansal - Wells Fargo

Elaine Kim - Cantor Fitzgerald

Tim Lugo - Williams Blair

Operator

Good afternoon ladies and gentlemen, and thank you for standing by. Welcome to the Xenon Pharmaceuticals Report, Second Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. [Operator instructions].

I will now turn the call over to Sherry Aulin, Chief Financial Officer.

Sherry Aulin

Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon’s Second Quarter 2023 financial and operating results.

Joining me are Ian Mortimer, Xenon’s President and Chief Executive Officer. Dr. Chris Kenney, Xenon’s Chief Medical Officer and Dr. Chris Von Seggern, Xenon’s Chief Commercial Officer Ian will open today's call with a summary of our proprietary pipeline programs and Chris Kenney will provide an overview of our ongoing XEN1101 clinical program.

I will summarize our financial results, progress within our partnered programs, and our anticipated Company milestone events. Chris Von Seggern will be available during our Q&A session to address questions about our commercialization strategies.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical trials, the anticipated presentation of data from clinical trials, the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of our and our partners' product candidates, the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in our XEN1101 and other development programs, the timing and results of our interactions with regulators, our ability to successfully develop and obtain regulatory approval of XEN1101 and our other product candidates, anticipated enrollment in our clinical trials and the timing thereof, and our expectation that we will have sufficient cash to fund operations into 2026.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statement. Today's press release summarizing Xenon's second quarter financial results and the accompanying annual report on Form 10-Q will be made available under the "Investors" section of our website at www.xenon-pharma.com and filed with the SEC and on SEDAR.